Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ramucirumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ramucirumab overview

Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated as the solution for injection for intravenous route o administration. Cyramza as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced  or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine-or platinum-containing chemotherapy, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy, in combination with FOLFIRI (irinotecan, folinic acid, and 5 -fluorouracil), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been previously treated with sorafenib. Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.

The drug candidate is under development for the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT), hepatocellular carcinoma, malignant mesothelioma, refractory/relapsed synovial sarcoma, pancreatic adenocarcinoma, adenocarcinoma of the gastroesophageal junction, bladder cancer, urethral cancer, non-small cell lung carcinoma, squamous non-small cell lung cancer, metastatic colorectal cancer, progressive carcinoid tumors, squamous cell carcinoma of the esophagus, pancreatic neuroendocrine tumor, gallbladder cancer, small-cell lung cancer and metastatic biliary tract cancer, metastatic thymic carcinoma, gastroesophageal junction region (GEJ) cancer, pediatric solid tumors including CNS, non-CNS tumors. The drug candidate was also under development for the treatment of HER2 negative metastatic breast cancer and gastric cancer as first-line therapy, fallopian tube cancer, peritoneal tumor, epithelial ovarian cancer, metastatic hormone refractory (castration-resistant, androgen-independent) prostate cancer, metastatic melanoma, bladder cancer, metastatic transitional cell cancer (urothelial cell cancer) including bladder cancer, urethral cancer, ureter cancer, recurrent glioblastoma multiforme (GBM), mantle cell lymphoma,  HER2 positive metastatic breast cancer as second-line therapy, metastatic renal cell carcinoma, signet ring cell squamous cell carcinoma. It is administered through subcutaneous route.

Eli Lilly and Co overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

For a complete picture of Ramucirumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.